Search Results - "Yoshio Sumida"

Current and future pharmacological therapies for NAFLD/NASH by Sumida, Yoshio, Yoneda, Masashi

“…Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and…”
Get full text

Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis by Sumida, Yoshio, Nakajima, Atsushi, Itoh, Yoshito

“…It is estimated that 30%of the adult population in Japan is affected by nonalcoholic fatty liver disease(NAFLD).Fatty changes of the liver are generally…”
Get full text

Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons by Sumida, Yoshio

Get full text

Phase 3 drug pipelines in the treatment of non‐alcoholic steatohepatitis by Sumida, Yoshio, Okanoue, Takeshi, Nakajima, Atsushi

“…Non‐alcoholic steatohepatitis (NASH), which is a more severe form of non‐alcoholic fatty liver disease, can at least partly lead to cirrhosis, hepatocellular…”
Get full text

COVID-19-associated liver injury (COVALI): role of hepatologists by Sumida, Yoshio, Yoneda, Masashi

Get full text

Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review by Kamada, Yoshihiro, Takahashi, Hirokazu, Shimizu, Masahito, Kawaguchi, Takumi, Sumida, Yoshio, Fujii, Hideki, Seko, Yuya, Fukunishi, Shinya, Tokushige, Katsutoshi, Nakajima, Atsushi, Okanoue, Takeshi

“…Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases worldwide, including in Japan. The Japanese Society of…”
Get full text

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial) by Sumida, Yoshio, Murotani, Kenta, Saito, Miyoko, Tamasawa, Atsuko, Osonoi, Yusuke, Yoneda, Masashi, Osonoi, Takeshi

“…Aims No pharmacological therapies are approved for non‐alcoholic fatty liver disease (NAFLD). Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, has…”
Get full text

Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012 by Nishioji, Kenichi, Sumida, Yoshio, Kamaguchi, Mai, Mochizuki, Naomi, Kobayashi, Masao, Nishimura, Takeshi, Yamaguchi, Kanji, Itoh, Yoshito

“…Background Non-alcoholic fatty liver disease (NAFLD) in non-obese subjects is not rare in Japan, but it has not been clearly described. To clarify its…”
Get full text

The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study by Ishiba, Hiroshi, Sumida, Yoshio, Tanaka, Saiyu, Yoneda, Masato, Hyogo, Hideyuki, Ono, Masafumi, Fujii, Hideki, Eguchi, Yuichiro, Suzuki, Yasuaki, Yoneda, Masashi, Takahashi, Hirokazu, Nakahara, Takashi, Seko, Yuya, Mori, Kojiro, Kanemasa, Kazuyuki, Shimada, Keiji, Imai, Sunsuke, Imajo, Kento, Kawaguchi, Takumi, Nakajima, Atsushi, Chayama, Kazuaki, Saibara, Toshiji, Shima, Toshihide, Fujimoto, Kazuma, Okanoue, Takeshi, Itoh, Yoshito

“…Background The FIB4 index is clinically useful, but because its formula includes age, the appropriate cutoff point may differ by age group. Here, new FIB4…”
Get full text

Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus by Sumida, Yoshio, Seko, Yuya, Yoneda, Masashi

“…Liver‐related diseases are the leading causes of death in patients with type 2 diabetes mellitus (T2DM) in Japan. Type 2 diabetes mellitus is closely…”
Get full text

Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review by Eguchi, Yuichiro, Wong, Gabriel, Akhtar, Omar, Sumida, Yoshio

“…Despite the invasive nature of liver biopsy, it remains the current standard for diagnosing non‐alcoholic steatohepatitis (NASH) and fibrosis staging. Given…”
Get full text

simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease by Sumida, Yoshio, Yoneda, Masato, Hyogo, Hideyuki, Yamaguchi, Kanji, Ono, Masafumi, Fujii, Hideki, Eguchi, Yuichiro, Suzuki, Yasuaki, Imai, Shunsuke, Kanemasa, Kazuyuki, Fujita, Koji, Chayama, Kazuaki, Yasui, Kohichiroh, Saibara, Toshiji, Kawada, Norifumi, Fujimoto, Kazuma, Kohgo, Yutaka, Okanoue, Takeshi

“…Background Liver histology is the gold standard for the diagnosis of nonalcoholic steatohepatitis (NASH). Noninvasive, simple, reproducible, and reliable…”
Get full text

HOMA‐IR: An independent predictor of advanced liver fibrosis in nondiabetic non‐alcoholic fatty liver disease by Fujii, Hideki, Imajo, Kento, Yoneda, Masato, Nakahara, Takashi, Hyogo, Hideyuki, Takahashi, Hirokazu, Hara, Tasuku, Tanaka, Saiyu, Sumida, Yoshio, Eguchi, Yuichiro, Chayama, Kazuaki, Nakajima, Atsushi, Nishimoto, Naoki, Kawada, Norifumi

“…Background and Aim Although non‐alcoholic fatty liver disease (NAFLD) is common in the general population, identifying patients with advanced fibrosis remains…”
Get full text

Role of vitamin E in the treatment of non-alcoholic steatohepatitis by Sumida, Yoshio, Yoneda, Masato, Seko, Yuya, Takahashi, Hirokazu, Hara, Nagisa, Fujii, Hideki, Itoh, Yoshito, Yoneda, Masashi, Nakajima, Atsushi, Okanoue, Takeshi

“…Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD), can progress to cirrhosis, hepatocellular carcinoma (HCC),…”
Get full text

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin by Ogawa, Yuji, Imajo, Kento, Honda, Yasushi, Kessoku, Takaomi, Tomeno, Wataru, Kato, Shingo, Fujita, Koji, Yoneda, Masato, Saito, Satoru, Saigusa, Yusuke, Hyogo, Hideyuki, Sumida, Yoshio, Itoh, Yoshito, Eguchi, Kosei, Yamanaka, Takeharu, Wada, Koichiro, Nakajima, Atsushi

“…Although previous studies have indicated important roles of palmitate, a saturated fatty acid, in the pathogenesis of nonalcoholic fatty liver disease (NAFLD),…”
Get full text

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population by Sumida, Yoshio, Yoneda, Masato, Hyogo, Hideyuki, Itoh, Yoshito, Ono, Masafumi, Fujii, Hideki, Eguchi, Yuichiro, Suzuki, Yasuaki, Aoki, Noriaki, Kanemasa, Kazuyuki, Fujita, Koji, Chayama, Kazuaki, Saibara, Toshiji, Kawada, Norifumi, Fujimoto, Kazuma, Kohgo, Yutaka, Yoshikawa, Toshikazu, Okanoue, Takeshi

“…A reliable and inexpensive noninvasive marker of hepatic fibrosis is required in patients with nonalcoholic fatty liver disease (NAFLD). FIB4 index (based on…”
Get full text

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers by Kawaguchi, Takahisa, Shima, Toshihide, Mizuno, Masayuki, Mitsumoto, Yasuhide, Umemura, Atsushi, Kanbara, Yoshihiro, Tanaka, Saiyu, Sumida, Yoshio, Yasui, Kohichiro, Takahashi, Meiko, Matsuo, Keitaro, Itoh, Yoshito, Tokushige, Katsutoshi, Hashimoto, Etsuko, Kiyosawa, Kendo, Kawaguchi, Masanori, Itoh, Hiroyuki, Uto, Hirofumi, Komorizono, Yasuji, Shirabe, Ken, Takami, Shiro, Takamura, Toshinari, Kawanaka, Miwa, Yamada, Ryo, Matsuda, Fumihiko, Okanoue, Takeshi

“…The genetic factors affecting the natural history of nonalcoholic fatty liver disease (NAFLD), including the development of nonalcoholic steatohepatitis (NASH)…”
Get full text

Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works by Eguchi, Yuichiro, Wong, Gabriel, Lee, I‐Heng, Akhtar, Omar, Lopes, Ricardo, Sumida, Yoshio

“…Aims Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality in Japan. As the treatment of viral hepatitis improves, non‐alcoholic…”
Get full text

Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study by Fujii, Hideki, Iwaki, Michihiro, Hayashi, Hideki, Toyoda, Hidenori, Oeda, Satoshi, Hyogo, Hideyuki, Kawanaka, Miwa, Morishita, Asahiro, Munekage, Kensuke, Kawata, Kazuhito, Yamamura, Sakura, Sawada, Koji, Maeshiro, Tatsuji, Tobita, Hiroshi, Yoshida, Yuichi, Naito, Masafumi, Araki, Asuka, Arakaki, Shingo, Kawaguchi, Takumi, Noritake, Hidenao, Ono, Masafumi, Masaki, Tsutomu, Yasuda, Satoshi, Tomita, Eiichi, Yoneda, Masato, Kawada, Norifumi, Tokushige, Akihiro, Kamada, Yoshihiro, Takahashi, Hirokazu, Ueda, Shinichiro, Aishima, Shinichi, Sumida, Yoshio, Nakajima, Atsushi, Okanoue, Takeshi

“…There are no detailed reports of clinical outcomes in Asian patients with nonalcoholic fatty liver disease (NAFLD) who undergo liver biopsy. We aimed to…”
Get full text

Current and new pharmacotherapy options for non-alcoholic steatohepatitis by Sumida, Yoshio, Yoneda, Masato, Ogawa, Yuji, Yoneda, Masashi, Okanoue, Takeshi, Nakajima, Atsushi

“…There is an unmet medical need for an effective anti-fibrotic treatment for NASH with advanced fibrosis. The authors review the current and novel agents for…”
Get more information